Vertex recently said the product may deliver more than $100 million in revenue in the 2025 full year. But it's important to ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of ...

On the one hand, these stocks tend to have explosive growth potential, much more so than most of their larger counterparts.

CRISPR has incurred nearly $500 million in losses over the past four quarters. It's burning through cash as the result of its ...

Healthcare stocks as a group have not performed on par with broader equities this year. However, that doesn't mean investors ...

Detailed price information for Ark Genomic Revolution ETF (ARKG-A) from The Globe and Mail including charting and trades.

In the latest close session, CRISPR Therapeutics AG (CRSP) was down 2.5% at $56.46. The stock's performance was behind the S&P 500's daily gain of 0.46%. On the other hand, the Dow registered a gain ...